Diabetic Macular Edema Epidemiology Analysis and Forecast, 2021-2031

Pages: 26 Published: July 28, 2022 Report Code: GDHCER300-22

In the 7MM total prevalent cases of diabetic macular edema epidemiology were 1,724,733 in 2021. The cases are expected to grow at an AGR of more than 1% during 2021-2031. Macular edema (ME) is a condition characterized by the thickening and swelling (edema) of the macula, which is the area of the retina that is responsible for central vision. The pathogenesis of ME is complex and multifactorial and mainly results from the disruption of the blood-retinal barrier, leading to the accumulation of fluid and serum macromolecules in the intercellular space.

DME market research report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for DME in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of DME. The diagnosed prevalent cases of DME are further segmented by age (20 years and older), sex, involvement of the eye (center-involving DME and non-center-involving DME) and by type of DME (focal-pattern DME and diffuse-pattern DME). The following data describes epidemiology of DME.

Diabetic Macular Edema Epidemiology, Outlook

Diabetic Macular Edema Epidemiology, Outlook

For more insights, download a free report sample

Age-Specific 12-Month Diagnosed Prevalent Cases of DME

The key age segments in the 12-month diagnosed prevalent cases of DME are, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and more than 80. In 2021, for the 7MM combined, adults ages 60–69 years contributed the highest proportion of the diagnosed prevalent cases of DME.

Age-Specific 12-Month Diagnosed Prevalent Cases of DME

Age-Specific 12-Month Diagnosed Prevalent Cases of DME

For more key age segment insights, download a free report sample

COVID-19 Impact in the DME Epidemiology Market

The coronavirus disease 2019 (COVID-19) is likely to have far-reaching consequences as global healthcare systems have been redirected to focus on fighting the pandemic. The impact of COVID-19 may include a shortage of medical staff, decreased access to treatment, a delay in diagnosis, decreased survival, and an increase in disease incidence related to coronavirus infections. Intravitreal therapy is widely recognized as a major milestone in ophthalmology, being one of the most commonly performed ocular procedures for DME. The spread of coronavirus disease led to a significant downsizing of non-urgent treatments provided for ocular disorders, including intravitreal therapy.

Market report overview

Market size 2021 1,724,733 cases
AGR% (2021-2031) >1%
Key age segments  20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and >80

Scope

  • The Diabetic Macular Edema (DME) Epidemiology Report and Model provide an overview of the risk factors and global trends of DME in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of DME. The diagnosed prevalent cases of DME are further segmented by age (20 years and older), sex, and involvement of the eye (center-involving DME and non-center-involving DME) and by type of DME (focal-pattern DME and diffuse-pattern DME). The model associated with the report also provides the diagnosed prevalent cases of clinically significant DME among the diagnosed DME population.
  • The DME epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
  • The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

  • The Diabetic Macular Edema (DME) Epidemiology series will allow you to:
  • Develop business strategies by understanding the trends shaping and driving the global DME market.
  • Quantify patient populations in the global DME market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for DME therapeutics in each of the markets covered.
  • Understand magnitude of DME population

Table of Contents

| About GlobalData

1 Diabetic Macular Edema: Executive Summary

1.1 Catalyst

1.2 Related reports

1.3 Upcoming reports

2 Epidemiology

2.1 Disease background

2.2 Risk factors and comorbidities

2.3 Global and historical trends

2.4 7MM forecast methodology

2.4.1 Sources

2.4.2 Forecast assumptions and methods

2.4.3 Diagnosed prevalent cases of DME among the diagnosed DR population

2.4.4 Diagnosed prevalent cases of DME by involvement of the eye

2.4.5 Diagnosed prevalent cases of DME by type

2.5 Epidemiological forecast for DME (2021–31)

2.5.1 Diagnosed prevalent cases of DME among the diagnosed DR population

2.5.2 Age-specific diagnosed prevalent cases of DME among the diagnosed DR population

2.5.3 Sex-specific diagnosed prevalent cases of DME among the diagnosed DR population

2.5.4 Diagnosed prevalent cases of DME by involvement of the eye

2.5.5 Diagnosed prevalent cases of DME by type

2.6 Discussion

2.6.1 Epidemiological forecast insight

2.6.2 COVID-19 impact

2.6.3 Limitations of the analysis

2.6.4 Strengths of the analysis

3 Appendix

3.1 Bibliography

3.2 About the authors

3.2.1 Epidemiologist

3.2.2 Reviewers

3.2.3 Global Director of Therapy Analysis and Epidemiology

3.2.4 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

List of Tables

Table 1: Summary of newly added data types

Table 2: Summary of updated data types

Table 3: Risk factors and comorbid conditions associated with DME

List of Figures

Figure 1: 7MM, diagnosed prevalent cases of DME, both sexes, N, ages ≥20 years, 2021 and 2031

Figure 2: 7MM, diagnosed prevalence of DME (%), men and women, ages ≥20 years, 2021

Figure 3: 7MM, sources used and not used to forecast the diagnosed prevalent cases of DME

Figure 4: 7MM, sources used to forecast the diagnosed prevalent cases of DME by involvement of the eye

Figure 5: 7MM, sources used to forecast the diagnosed prevalent cases of DME by type

Figure 6: 7MM, diagnosed prevalent cases of DME, N, both sexes, ages ≥20 years, 2021

Figure 7: 7MM, diagnosed prevalent cases of DME by age group, N, both sexes, 2021

Figure 8: 7MM, diagnosed prevalent cases of DME by sex, N, ages ≥20 years, 2021

Figure 9: 7MM, diagnosed prevalent cases of DME by involvement of the eye, N, both sexes, ages ≥20 years, 2021

Figure 10: 7MM, diagnosed prevalent cases of DME by type, N, both sexes, ages ≥20 years, 2021

Frequently Asked Questions

The total number of prevalent cases of DME were 1,724,733 in 2021.

The DME epidemiology market is expected to grow at an AGR of more than 1%.

The key age segments in the 12-month diagnosed prevalent cases of DME are 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and more than 80.

$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about our multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Testimonial

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods
Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.

Diabetic Macular Edema
New
Diabetic Foot Ulcers Treatment Market Size, Share and Trends Analysis…
$3,950 | November 2022
Diabetic Macular Edema
New
Dry Eye Syndrome Market Size, Share and Trends Analysis by…
$3,950 | November 2022
Diabetic Macular Edema
New
Non-Small Cell Lung Cancer Marketed and Pipeline Drugs Assessment, Clinical…
$3,495 | November 2022